341 related articles for article (PubMed ID: 29946255)
1. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials.
Yan YD; Zhang C; Shen L; Su YJ; Liu XY; Wang LW; Gu ZC
Front Pharmacol; 2018; 9():575. PubMed ID: 29946255
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
3. Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis.
Yan YD; Ding Z; Pan MM; Xia Q; Cui JJ; Wang LW; Zhang C; Gu ZC
Front Cardiovasc Med; 2020; 7():586020. PubMed ID: 33304929
[No Abstract] [Full Text] [Related]
4. Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Gu ZC; Zhou LY; Shen L; Zhang C; Pu J; Lin HW; Liu XY
Front Pharmacol; 2018; 9():348. PubMed ID: 29692734
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
[TBL] [Abstract][Full Text] [Related]
6. Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III clinical trials.
Gu ZC; Kong LC; Yang SF; Wei AH; Wang N; Ding Z; Zhang C; Liu XY; Zheng YL; Lin HW
Cardiovasc Diagn Ther; 2019 Oct; 9(5):410-419. PubMed ID: 31737513
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
[TBL] [Abstract][Full Text] [Related]
8. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials.
Sardar P; Chatterjee S; Mukherjee D
Drugs; 2013 Jul; 73(11):1171-82. PubMed ID: 23812923
[TBL] [Abstract][Full Text] [Related]
10. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis.
Sidahmed S; Abdalla A; Kheiri B; Bala A; Salih M; Bachuwa G; Kafri Z; Kuderer NM; Lyman GH
Crit Rev Oncol Hematol; 2020 Aug; 152():103005. PubMed ID: 32540780
[TBL] [Abstract][Full Text] [Related]
12. New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.
Hirschl M; Kundi M
Vasa; 2014 Sep; 43(5):353-64. PubMed ID: 25147012
[TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies.
Liu ZY; Zhang HX; Ma LY; Mu GY; Xie QF; Zhou S; Wang ZN; Wang Z; Hu K; Xiang Q; Cui YM
BMC Cardiovasc Disord; 2022 Mar; 22(1):105. PubMed ID: 35287588
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients.
Pathak R; Giri S; Karmacharya P; Aryal MR; Poudel DR; Ghimire S; Jehangir A; Shaikh B; Rettew A; Donato AA
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):934-9. PubMed ID: 26258674
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.
Caldeira D; Barra M; Ferreira A; Rocha A; Augusto A; Pinto FJ; Costa J; Ferreira JJ
Aliment Pharmacol Ther; 2015 Dec; 42(11-12):1239-49. PubMed ID: 26434935
[TBL] [Abstract][Full Text] [Related]
16. Net clinical benefit of DOACs vs. usual anticoagulation treatment in venous thromboembolism and active cancer: systematic review and meta-analysis.
Michalopoulou H; Polyzos D; Thomopoulos C; Makavos G; Papamikroulis GA; Nikova A; Zakynthinos GΕ; Vavouranakis M; Siasos G; Vavouranakis E
J Thromb Thrombolysis; 2023 Jan; 55(1):92-101. PubMed ID: 36307630
[TBL] [Abstract][Full Text] [Related]
17. Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis.
Miller CS; Dorreen A; Martel M; Huynh T; Barkun AN
Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1674-1683.e3. PubMed ID: 28458008
[TBL] [Abstract][Full Text] [Related]
18. Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Squizzato A; Lussana F; Cattaneo M
Thromb Haemost; 2015 Aug; 114(2):237-44. PubMed ID: 25946985
[TBL] [Abstract][Full Text] [Related]
19. Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: A pooled analysis of randomized controlled trials and real-world studies.
Zhang C; Gu ZC; Ding Z; Shen L; Pan MM; Zheng YL; Lin HW; Pu J
Thromb Res; 2019 Feb; 174():16-23. PubMed ID: 30551039
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S
PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
